Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.37 |
| ▸ | POLQ | O75417 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.34 |
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582314 | 0.90 | PDE4A (0.43) | SLC22A12PTPN11MAP4K4CSNK2A1CSNK2A2 | |
| SCHEMBL5581713 | 0.86 | CSNK2A1 (0.42) | MAP4K4CSNK2A1CHEK1TBK1CSNK2A2 | |
| SCHEMBL5582036 | 0.85 | PTPN11 (0.43) | PTPN11MAP4K4CSNK2A1CHEK1TBK1 | |
| SCHEMBL5582330 | 0.85 | CSNK2A1 (0.48) | MAP4K4CSNK2A1TBK1CSNK2A2CSNK2B | |
| SCHEMBL5582062 | 0.84 | MKNK1 (0.44) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL5582010 | 0.83 | CSNK2A2 (0.47) | MAP4K4CSNK2A1TBK1CSNK2A2CSNK2B | |
| SCHEMBL5582255 | 0.82 | CSNK2A1 (0.43) | MAP4K4CSNK2A1TBK1CSNK2A2CSNK2B | |
| SCHEMBL5582325 | 0.81 | KMO (0.43) | MAP4K4CSNK2A1TBK1CSNK2A2CSNK2B | |
| SCHEMBL5581557 | 0.80 | POLQ (0.35) | MAP4K4POLQLRRK2 | |
| SCHEMBL5582267 | 0.79 | CSNK2A1 (0.46) | MAP4K4CSNK2A1CSNK2A2CSNK2BLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | SLC22A12 917/4885PTPN11 542/4885MAP4K4 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.